← Back to Search

Other

PF-06882961 160 mg BID, 2-week titration (Cohorts 1 and 2) for Obesity

Phase 2
Waitlist Available
Research Sponsored by Pfizer
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up cohorts 1 and 2: baseline, week 2, 4, 6, 8, 10, 12, 16, 18, 22 and 26; cohort 3: baseline, week 4, 8, 12, 16, 20, 24, 28 and 32
Awards & highlights

Summary

This trial will study whether PF-06882961 is safe and effective in adults with obesity. The study will last for 26 weeks and participants will be monitored for any adverse effects.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~cohorts 1 and 2: baseline, week 2, 4, 6, 8, 10, 12, 16, 18, 22 and 26; cohort 3: baseline, week 4, 8, 12, 16, 20, 24, 28 and 32
This trial's timeline: 3 weeks for screening, Varies for treatment, and cohorts 1 and 2: baseline, week 2, 4, 6, 8, 10, 12, 16, 18, 22 and 26; cohort 3: baseline, week 4, 8, 12, 16, 20, 24, 28 and 32 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Secondary outcome measures
Absolute change from baseline in fasting plasma glucose
Absolute change from baseline in hemoglobin A1c
Absolute change from baseline in waist circumference
+9 more

Trial Design

13Treatment groups
Experimental Treatment
Placebo Group
Group I: PF-06882961 80 mg BID, 4-week titration (Cohort 3)Experimental Treatment1 Intervention
The dose will be titrated with 4 weeks of dosing at each step to reach the target dose of 80 mg BID.
Group II: PF-06882961 80 mg BID, 1-week titration (Cohort 1)Experimental Treatment1 Intervention
The dose will be titrated with 1 week of dosing at each step to reach the target dose of 80 mg BID.
Group III: PF-06882961 40 milligrams (mg) twice daily (BID), 1-week titration (Cohort 1)Experimental Treatment1 Intervention
The dose will be titrated with 1 week of dosing at each step to reach the target dose of 40 mg BID.
Group IV: PF-06882961 200 mg BID, 4-week titration (Cohort 3)Experimental Treatment1 Intervention
The dose will be titrated with 4 weeks of dosing at each step to reach the target dose of 200 mg BID.
Group V: PF-06882961 200 mg BID, 2-week titration (Cohorts 1 and 2)Experimental Treatment1 Intervention
The dose will be titrated with 2 weeks of dosing at each step to reach the target dose of 200 mg BID.
Group VI: PF-06882961 200 mg BID, 1-week titration (Cohort 1)Experimental Treatment1 Intervention
The dose will be titrated with 1 week of dosing at each step to reach the target dose of 200 mg BID.
Group VII: PF-06882961 160 mg BID, 2-week titration (Cohorts 1 and 2)Experimental Treatment1 Intervention
The dose will be titrated with 2 weeks of dosing at each step to reach the target dose of 160 mg BID.
Group VIII: PF-06882961 160 mg BID, 1-week titration (Cohort 1)Experimental Treatment1 Intervention
The dose will be titrated with 1 week of dosing at each step to reach the target dose of 160 mg BID.
Group IX: PF-06882961 140 mg BID, 4-week titration (Cohort 3)Experimental Treatment1 Intervention
The dose will be titrated with 4 weeks of dosing at each step to reach the target dose of 140 mg BID.
Group X: PF-06882961 120 mg BID, 2-week titration (Cohorts 1 and 2)Experimental Treatment1 Intervention
The dose will be titrated with 2 weeks of dosing at each step to reach the target dose of 120 mg BID.
Group XI: PF-06882961 120 mg BID, 1-week titration (Cohort 1)Experimental Treatment1 Intervention
The dose will be titrated with 1 week of dosing at each step to reach the target dose of 120 mg BID.
Group XII: Placebo (Cohorts 1 and 2)Placebo Group1 Intervention
Group XIII: Placebo (Cohort 3)Placebo Group1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
PF-06882961 (Cohort 3)
2021
Completed Phase 2
~630
PF-06882961 (Cohorts 1 and 2)
2021
Completed Phase 2
~630

Find a Location

Who is running the clinical trial?

PfizerLead Sponsor
4,595 Previous Clinical Trials
12,868,140 Total Patients Enrolled
40 Trials studying Obesity
116,342 Patients Enrolled for Obesity
Pfizer CT.gov Call CenterStudy DirectorPfizer
3,496 Previous Clinical Trials
10,044,749 Total Patients Enrolled
29 Trials studying Obesity
119,596 Patients Enrolled for Obesity

Media Library

PF-06882961 (Other) Clinical Trial Eligibility Overview. Trial Name: NCT04707313 — Phase 2
PF-06882961 (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04707313 — Phase 2
Obesity Research Study Groups: PF-06882961 160 mg BID, 2-week titration (Cohorts 1 and 2), PF-06882961 200 mg BID, 4-week titration (Cohort 3), PF-06882961 200 mg BID, 2-week titration (Cohorts 1 and 2), PF-06882961 120 mg BID, 2-week titration (Cohorts 1 and 2), PF-06882961 80 mg BID, 4-week titration (Cohort 3), PF-06882961 140 mg BID, 4-week titration (Cohort 3), PF-06882961 160 mg BID, 1-week titration (Cohort 1), PF-06882961 200 mg BID, 1-week titration (Cohort 1), Placebo (Cohorts 1 and 2), PF-06882961 40 milligrams (mg) twice daily (BID), 1-week titration (Cohort 1), PF-06882961 80 mg BID, 1-week titration (Cohort 1), PF-06882961 120 mg BID, 1-week titration (Cohort 1), Placebo (Cohort 3)
Obesity Clinical Trial 2023: PF-06882961 Highlights & Side Effects. Trial Name: NCT04707313 — Phase 2
Obesity Patient Testimony for trial: Trial Name: NCT04707313 — Phase 2
~143 spots leftby Jul 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top